A 12 Month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Different Dosing Regimens of 0.5 mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularisation Secondary to Pathologic Myopia

Trial Profile

A 12 Month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Different Dosing Regimens of 0.5 mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularisation Secondary to Pathologic Myopia

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Ranibizumab (Primary) ; Verteporfin
  • Indications Choroidal neovascularisation; Degenerative myopia
  • Focus Registrational; Therapeutic Use
  • Acronyms RADIANCE
  • Sponsors Novartis
  • Most Recent Events

    • 05 Jan 2017 According to a Genentech media release, the US FDA has approved ranibizumab (Lucentis) for the treatment of patients with myopic choroidal neavascularization based on results from this trial.
    • 11 Oct 2016 According to a Roche media release, the US FDA has accepted a supplemental Biologics License Application (sBLA) for ranibizumab (Lucentis) for review for the treatment of myopic choroidal neovascularization based on results from this trial.
    • 15 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top